Novartis
NEWS
BeiGene and Novartis’ unresectable hepatocellular carcinoma treatment, Tislelizumab, is gaining ground as a potential treatment for advanced liver cancer.
Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted
Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.
Total sales for the quarter were $12.8 billion, with its innovative medicines, which include key assets, bringing in $10.8 billion.
Recent advances in precision medicine and genomics have launched an explosion in immunotherapies that are resulting in real cures and earlier diagnoses - and more healthy years for individuals.
Beigene and Novartis announced the FDA has deferred action on the BLA for tislelizumab until inspections of facilities in China can be completed.
At the end of June, Novartis announced the latest data readouts in a long string of successes for tislelizumab. BioSpace spoke with Ken Kato, an investigator on the most recent RATIONALE 306 trial.
As the calendar pages continue to turn, the FDA has a slew of novel drugs awaiting approval, several of which are likely to become game-changers for patients and key assets for companies.
Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.
JOBS
IN THE PRESS